<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555139</url>
  </required_header>
  <id_info>
    <org_study_id>CRH108571</org_study_id>
    <nct_id>NCT00555139</nct_id>
  </id_info>
  <brief_title>A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder</brief_title>
  <official_title>Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Single-dose Administration in Subjects With Social Anxiety Disorder (SAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To compare by neuroimaging techniques and public speaking, the way social anxiety patients
      respond after the administration of GW876008, GSK561679, alprazolam and placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of fMRI activation in amygdala of subjects with SAD during an emotional task after having received different compounds. Change in the VAS score in response to Public Speaking stress after having received different compounds.</measure>
    <time_frame>over 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of fMRI activation patterns in all brain areas in subjects with SAD during an emotional task or resting state. Changes of cortisol levels and other stress indicators in response to Public Speaking stress.</measure>
    <time_frame>over 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pk samples:</measure>
    <time_frame>2,4-5,8h post-dose (over 3 weeks,w 1,2&amp;3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol, ACTH:</measure>
    <time_frame>5h20',5h35', 6h &amp; 7h post dose (over 6 weeks,w 1,2,3 &amp;6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indicators of physiological state during the fMRI session:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR), Respiratory rate (RR), ventilation (pneumatic pletismography), and carbon dioxide percutaneous measurements monitored during the whole procedure (control and exploratory profile tests).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) measurements of distress</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maddox wing test.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire for s√©dation.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of the various compounds to derive pharmacokinetic parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability will be evaluated by adverse event monitoring, physical examination, ECG, vital signs and laboratory parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK561679</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
    <other_name>GSK561679</other_name>
    <other_name>GW876008</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Outpatient with a primary diagnosis of Social Anxiety

          -  LSAS score of 50 or more.

          -  Men or women who are between 18 and 64 years of age. Women will be included in this
             study only if the reproductive toxicology data available at the time of study start
             will allow their inclusion, in accordance with regulatory requirements.

          -  Body weight &gt; 50 kg and BMI within the range 18.5 - 31.0 kg/m2.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  The subject must be able to read, comprehend and record information.

          -  A signed and dated written informed consent is obtained from the subject.

          -  Subjects willing to restrict alcohol intake to 4 unit of alcohol or less per day. A
             unit is equivalent to 300 ml of beer or one measure of spirits or one glass of wine.

          -  Women must be of non child bearing potential or commit to consistent and correct use
             of an acceptable method of birth control that must be recorded on the source
             documentation at screening and verified for continued compliance at each visit; GSK
             acceptable contraceptive methods, when used consistently and in accordance with both
             the product label and the instructions of a physician, are as follows:

          -  Subjects with a history of peptic ulcer disease (PUD) with a known aetiology must
             provide documentation by a gastroenterologist of the aetiology of the PUD and that
             effective treatment was provided with full eradication of ulcers and symptoms.

        Exclusion criteria:

          -  Any concomitant drug dosing 24 h before each dosing.

          -  Any history of a clinically significant abnormality of the neurological system
             (including dementia and other cognitive disorders or significant head injury) or any
             history of seizure (excluding febrile seizure).

          -  Subjects with an unstable medical disorder or a disorder that would likely interfere
             with the action, absorption, distribution, metabolism or excretion of GW876008,
             GSK561679 or alprazolam, may pose a safety concern, or interfere with accurate
             assessment of safety.

          -  The subject has a current or recent (within six months) documented gastrointestinal
             disease

          -  Subject has symptoms of the presenting illness which are better accounted for by
             another diagnosis or subjects who meet DSM-IV criteria for any other Axis I disorder
             as a primary diagnosis currently or within 6 months prior to the screening visit or A
             current DSM-IV-TR diagnosis of Antisocial or Borderline Personality Disorder,
             Dementia, or another current DSM-IV-TR Axis II diagnosis that would suggest
             nonresponsiveness to pharmacotherapy or non-compliance with the protocol; or A
             current (or within six months prior to the Screening visit) diagnosis of anorexia
             nervosa or bulimia; or Subjects with a history of Schizophrenia, Schizoaffective
             Disorder, or a Bipolar Disorder.

          -  HAMD-17 score greater than 15.

          -  Subjects who are currently receiving regularly scheduled psychotherapy (individual or
             group, including cognitive behavioural therapy), plan to initiate psychotherapy
             during the trial or have received regularly scheduled psychotherapy during the 12
             week period prior to the Screening Visit.

          -  Subjects have any laboratory abnormality that in the investigator's judgment is
             considered to be clinically significant and not resolved by the Randomization Visit.

          -  The subject has a semi-supine systolic blood pressure less than 90mmHg (85mmHg for
             females) or greater than 140mmHg or a semi-supine diastolic blood pressure of less
             than 45mmHg or greater than 90mmHg; or a pulse rate less than 40bpm or more than
             90bpm.

          -  Women who have a positive serum Human Chorionic Gonadotropin (HCG) pregnancy test at
             screen visit, a positive urine dipstick test at Randomization, or who are lactating
             or planning to become pregnant within the next 2weeks after the Follow Up Visit.

          -  The subject has participated in a clinical trial and has received a drug or a new
             chemical entity within 60 days or 5 half-lives, or twice the duration of the
             biological effect of any drug(whichever is longer) prior to the first dose of current
             study medication.

          -  Exposure to more than four new chemical within 12 months prior to the first dosing
             day.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the physician responsible,
             contraindicates their participation.

          -  As a result of any of the medical interview, physical examination or screening
             investigations the physician responsible considers the subject unfit for the study.

          -  History of long QT syndrome (personal or family) or other cardiac conduction
             disorder, or other clinically significant cardiac disease.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John'sWort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless in the opinion of the Investigator and sponsor the
             medication will not interfere with the study procedures or compromise subject safety

          -  Subjects who, in the opinion of the investigator, would be noncompliant with the
             visit schedule or study procedures (e.g., illiteracy, planned vacations, or planned
             hospitalizations during the study).

          -  Subjects who are not euthyroid as evidenced by normal TSH. Subjects maintained with
             thyroid medication must be euthyroid for a period of at least six months prior to the
             screen visit.

          -  Subject's level of FSH falling outside normal range

          -  Subjects with diabetes or high risk of diabetes based on a documented history of
             impaired glucose tolerance.

          -  Subjects have any electrocardiographic (ECG) parameter outside of the
             Sponsor-specified ranges at either screen or randomization visit.

          -  Subjects who have had electroconvulsive therapy (ECT) or transcranial magnetic
             stimulation within the 6 months prior to the Screening Visit.

          -  Subjects, who are left-handed.

          -  The subject has a positive pre-study urine drug/ breath alcohol screen. A minimum
             list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine,
             Opiates, Cannabinoids and Benzodiazepines.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening.

          -  Documented history of hepato-biliary disease or abnormality in hepatic enzymesat
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcellona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mataro (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Terrassa - Barcelona</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 13, 2010</lastchanged_date>
  <firstreceived_date>November 5, 2007</firstreceived_date>
  <firstreceived_results_disposition_date>October 13, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>CRF-1 antagonists,</keyword>
  <keyword>depression,</keyword>
  <keyword>anxiety,</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Anti-Anxiety Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
